Shire presentations at ASH 2017 highlight commitment to furthering research and innovation in Hematology and Oncology
November 10 2017 - 7:00AM
YASTEST
Shire presentations at ASH 2017
highlight commitment to furthering research and innovation in
Hematology and Oncology
Lexington, Mass. - November 10,
2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), the leading
biotechnology company focused on serving people with rare diseases,
today announced the broad range of research it will present at the
59th American Society of Hematology (ASH) Annual Meeting, taking
place December 9-12, 2017, in Atlanta, Georgia. Shire's presence at
ASH spans its hematology and oncology franchises with 2 oral
presentations and 7 poster presentations.
"Shire's commitment to fighting rare disease,
particularly in hematology and oncology, is reflected in the
company's strong presence at ASH, one of the world's premier
medical conferences focused on blood disorders," said Howard B.
Mayer, M.D., SVP and ad-interim Head, Global Research and
Development, Shire. "We are committed to continuous and ambitious
innovation that helps advance the standards of care and improves
outcomes in these therapeutic categories where there remains
significant unmet patient need."
HEMATOLOGY
The research presented at ASH will showcase Shire's broad
hematology portfolio, which covers a wide range of rare bleeding
indications and highlights real-world safety and efficacy data. In
addition to presenting new research, Shire will share updates
related to its ongoing innovation and promising pipeline of
investigational treatments. Shire has provided a grant to support a
satellite symposium at ASH hosted by CMEology that is focused on
the latest strategies and innovations to help advance best
practices in the management of hemophilia:
-
Advancing
Standards in the Management of Hemophilia A: Contemporary
Strategies and Innovations. Friday, December 8, 2017,
6:00-10:00 p.m. EST. Hyatt Regency Atlanta, International Ballroom
North. For more details or to register, visit:
http://www.hematology.org/Annual-Meeting/FSS/2941.aspx
ONCOLOGY
Shire's expertise in rare and difficult-to-treat cancers includes
ongoing research into investigational pegylated asparaginase, as a
component of antineoplastic combination therapy in acute
lymphoblastic leukemia (ALL). The company's pipeline in oncology
includes assets being developed for the treatment of metastatic
pancreatic cancer, ALL, lung cancer, as well as early stage
checkpoint inhibitor and allogeneic CAR T targets. At ASH 2017,
Shire is co-supporting an Independent Medical Education program
organized by prIME-Oncology on:
-
Optimizing
Management of Acute Lymphoblastic Leukemia: From Adolescence to
Adults. Friday, December 8, 2017, 12:30-4:30 p.m. EST.
Hyatt Regency Atlanta, International Ballroom North. For more
details or to register, visit:
http://www.hematology.org/Annual-Meeting/FSS/2911.aspx
For further information please
contact:
Investor Relations |
|
|
Ian Karp |
ikarp@shire.com |
+1 781 482 9018 |
Robert Coates |
rcoates@shire.com |
+44 203 549 0874 |
Media |
|
|
Gwen Fisher |
gfisher@shire.com |
+1 781 482 9649 |
Molly Poarch |
molly.poarch@shire.com |
+1 312 965 3413 |
NOTES TO EDITORS
About Shire
Shire is the global leader in serving patients
with rare diseases. We strive to develop best-in-class therapies
across a core of rare disease areas including hematology,
immunology, genetic diseases, neuroscience, and internal medicine
with growing therapeutic areas in ophthalmics and oncology. Our
diversified capabilities enable us to reach patients in more than
100 countries who are struggling to live their lives to the
fullest.
We feel a strong sense of urgency to address unmet
medical needs and work tirelessly to improve people's lives with
medicines that have a meaningful impact on patients and all who
support them on their journey.
www.shire.com
Forward-Looking
Statements
Statements included herein that
are not historical facts, including without limitation statements
concerning future strategy, plans, objectives, expectations and
intentions, the anticipated timing of clinical trials and approvals
for, and the commercial potential of, inline or pipeline products,
are forward-looking statements. Such forward-looking statements
involve a number of risks and uncertainties and are subject to
change at any time. In the event such risks or uncertainties
materialize, Shire's results could be materially adversely
affected. The risks and uncertainties include, but are not limited
to, the following:
-
Shire's products may not be a commercial
success;
-
increased pricing pressures and limits on
patient access as a result of governmental regulations and market
developments may affect Shire's future revenues, financial
condition and results of operations;
-
Shire conducts its own manufacturing operations
for certain of its products and is reliant on third party contract
manufacturers to manufacture other products and to provide goods
and services. Some of Shire's products or ingredients are only
available from a single approved source for manufacture. Any
disruption to the supply chain for any of Shire's products may
result in Shire being unable to continue marketing or developing a
product or may result in Shire being unable to do so on a
commercially viable basis for some period of time;
-
the manufacture of Shire's products is subject
to extensive oversight by various regulatory agencies. Regulatory
approvals or interventions associated with changes to manufacturing
sites, ingredients or manufacturing processes could lead to, among
other things, significant delays, an increase in operating costs,
lost product sales, an interruption of research activities or the
delay of new product launches;
-
certain of Shire's therapies involve lengthy and
complex processes, which may prevent Shire from timely responding
to market forces and effectively managing its production
capacity;
-
Shire has a portfolio of products in various
stages of research and development. The successful development of
these products is highly uncertain and requires significant
expenditures and time, and there is no guarantee that these
products will receive regulatory approval;
-
the actions of certain customers could affect
Shire's ability to sell or market products profitably. Fluctuations
in buying or distribution patterns by such customers can adversely
affect Shire's revenues, financial conditions or results of
operations;
-
Shire's products and product candidates face
substantial competition in the product markets in which it
operates, including competition from generics;
-
adverse outcomes in legal matters, tax audits
and other disputes, including Shire's ability to enforce and defend
patents and other intellectual property rights required for its
business, could have a material adverse effect on the Company's
revenues, financial condition or results of operations;
-
inability to successfully compete for highly
qualified personnel from other companies and organizations;
-
failure to achieve the strategic objectives,
including expected operating efficiencies, cost savings, revenue
enhancements, synergies or other benefits at the time anticipated
or at all with respect to Shire's acquisitions, including NPS
Pharmaceuticals Inc., Dyax Corp. or Baxalta Incorporated may
adversely affect Shire's financial condition and results of
operations;
-
Shire's growth strategy depends in part upon its
ability to expand its product portfolio through external
collaborations, which, if unsuccessful, may adversely affect the
development and sale of its products;
-
a slowdown of global economic growth, or
economic instability of countries in which Shire does business, as
well as changes in foreign currency exchange rates and interest
rates, that adversely impact the availability and cost of credit
and customer purchasing and payment patterns, including the
collectability of customer accounts receivable;
-
failure of a marketed product to work
effectively or if such a product is the cause of adverse side
effects could result in damage to Shire's reputation, the
withdrawal of the product and legal action against Shire;
-
investigations or enforcement action by
regulatory authorities or law enforcement agencies relating to
Shire's activities in the highly regulated markets in which it
operates may result in significant legal costs and the payment of
substantial compensation or fines;
-
Shire is dependent on information technology and
its systems and infrastructure face certain risks, including from
service disruptions, the loss of sensitive or confidential
information, cyber-attacks and other security breaches or data
leakages that could have a material adverse effect on Shire's
revenues, financial condition or results of operations;
-
Shire incurred substantial additional
indebtedness to finance the Baxalta acquisition, which has
increased its borrowing costs may decrease its business
flexibility; and
a further list and description of risks,
uncertainties and other matters can be found in Shire's most recent
Annual Report on Form 10-K and in Shire's subsequent Quarterly
Reports on Form 10-Q, in each case including those risks outlined
in "ITEM 1A: Risk Factors", and in Shire's subsequent reports on
Form 8-K and other Securities and Exchange Commission filings, all
of which are available on Shire's website.
All forward-looking statements
attributable to us or any person acting on our behalf are expressly
qualified in their entirety by this cautionary statement. Readers
are cautioned not to place undue reliance on these forward-looking
statements that speak only as of the date hereof. Except to the
extent otherwise required by applicable law, we do not undertake
any obligation to update or revise forward-looking statements,
whether as a result of new information, future events or
otherwise.
###
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Shire plc via Globenewswire
Shire (LSE:SHP)
Historical Stock Chart
From Apr 2024 to May 2024
Shire (LSE:SHP)
Historical Stock Chart
From May 2023 to May 2024